ARS Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 206

Employees

  • Stock Symbol
  • SPRY

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.96
  • (As of Friday Closing)

ARS Pharmaceuticals General Information

Description

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11682 El Camino Real
  • Suite 300
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 11682 El Camino Real
  • Suite 300
  • San Diego, CA 92130
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ARS Pharmaceuticals Stock Performance

As of 20-Nov-2026, ARS Pharmaceuticals’s stock price is $2.96. Its current market cap is $298M with 101M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.96 $3.36 $2.44 - $13.15 $298M 101M 1.82M -$2.01

ARS Pharmaceuticals Financials Summary

As of 30-Sep-2026, ARS Pharmaceuticals has a trailing 12-month revenue of $122M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 381,449 961,138 820,785 284,490
Revenue 122,136 84,278 89,149 30
EBITDA (197,246) (179,448) (3,083) (54,365)
Net Income (199,868) (171,298) 7,998 (54,365)
Total Assets 251,484 327,652 351,153 233,188
Total Debt 121,807 96,374 0 274
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ARS Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ARS Pharmaceuticals‘s full profile, request access.

Request a free trial

ARS Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore ARS Pharmaceuticals‘s full profile, request access.

Request a free trial

ARS Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (curren
Pharmaceuticals
San Diego, CA
206 As of 2026

South San Francisco, CA
 

Lund, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ARS Pharmaceuticals Competitors (36)

One of ARS Pharmaceuticals’s 36 competitors is Rigel Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rigel Pharmaceuticals Formerly VC-backed South San Francisco, CA
Camurus Corporation Lund, Sweden
Indivior Corporate Backed or Acquired North Chesterfield, VA
Tioga Pharmaceuticals Formerly VC-backed San Diego, CA
BeOne Medicines Formerly PE-Backed Beijing, China
You’re viewing 5 of 36 competitors. Get the full list »

ARS Pharmaceuticals Patents

ARS Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250262173-A1 Intranasal epinephrine formulations and methods of use Pending 19-Feb-2024
WO-2022076905-A1 Alk5 inhibitors, conjugates, and uses thereof Inactive 09-Oct-2020
WO-2022006340-A1 Alk5 inhibitors, conjugates, and uses thereof Inactive 01-Jul-2020
AU-2021300362-A1 Anti-asgr1 antibody conjugates and uses thereof Inactive 01-Jul-2020
CA-3183993-A1 Anti-asgr1 antibody conjugates and uses thereof Pending 01-Jul-2020 A61K47/6803
To view ARS Pharmaceuticals’s complete patent history, request access »

ARS Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ARS Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ARS Pharmaceuticals‘s full profile, request access.

Request a free trial

ARS Pharmaceuticals Acquisitions (1)

ARS Pharmaceuticals’s most recent deal was a Merger/Acquisition with Silverback Therapeutics for . The deal was made on 08-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Silverback Therapeutics 08-Nov-2022 Merger/Acquisition Biotechnology
To view ARS Pharmaceuticals’s complete acquisitions history, request access »

ARS Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view ARS Pharmaceuticals’s complete esg history, request access »

ARS Pharmaceuticals FAQs

  • When was ARS Pharmaceuticals founded?

    ARS Pharmaceuticals was founded in 2015.

  • Where is ARS Pharmaceuticals headquartered?

    ARS Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of ARS Pharmaceuticals?

    ARS Pharmaceuticals has 206 total employees.

  • What industry is ARS Pharmaceuticals in?

    ARS Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is ARS Pharmaceuticals a private or public company?

    ARS Pharmaceuticals is a Public company.

  • What is ARS Pharmaceuticals’s stock symbol?

    The ticker symbol for ARS Pharmaceuticals is SPRY.

  • What is the current stock price of ARS Pharmaceuticals?

    As of 20-Nov-2026 the stock price of ARS Pharmaceuticals is $2.96.

  • What is the current market cap of ARS Pharmaceuticals?

    The current market capitalization of ARS Pharmaceuticals is $298M.

  • What is ARS Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for ARS Pharmaceuticals is $122M.

  • Who are ARS Pharmaceuticals’s competitors?

    Rigel Pharmaceuticals, Camurus, Indivior, Tioga Pharmaceuticals, and BeOne Medicines are some of the 36 competitors of ARS Pharmaceuticals.

  • What is ARS Pharmaceuticals’s annual earnings per share (EPS)?

    ARS Pharmaceuticals’s EPS for 12 months was -$2.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process